Bildkälla: Stockfoto

Xbrane Biopharma Q2 2023: A setback but not case altering - Redeye

Redeye considers Xbrane’s Q2 weak due to slower sales ramp-up than anticipated and postponed profitability. We lower our fair value range but the drastic 43% drop observed yesterday reflects an excessively pessimistic and short-term perspective on the company.

Redeye considers Xbrane’s Q2 weak due to slower sales ramp-up than anticipated and postponed profitability. We lower our fair value range but the drastic 43% drop observed yesterday reflects an excessively pessimistic and short-term perspective on the company.
Börsvärldens nyhetsbrev
ANNONSER